| Ytd | -2.65% | |
| 1y | -13.29% |
| Open | 26.60 | Prev Close | 26.82 | Low | 26.60 | High | 27.19 | Mkt Cap | 2.63B |
| Vol | 38.36K | Avg Vol | 175.48K | EPS | 1.23 | P/E | 21.80 | Forward P/E | 20.62 |
| Beta | 1.21 | Short Ratio | 9.57 | Inst. Own | 94.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 29.35 | 200-d Avg | 29.05 | 1yr Est | 35.00 |
ATS News
[url="]Interactive Brokers[/url] (Nasdaq: IBKR), an automated global broker, today announced the lau
ATS, BXBLY and SKY have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2026.
Investors need to pay close attention to ATS stock based on the movements in the options market late
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. (NASDAQ: FUSE), a leading provider of
Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at America
ATS, BFC and CMC have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2026.
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”)
Securitize and Cantor Equity Partners II Announce SEC Declaration of Effectiveness of Registration S
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
ATS NYSE: ATS reported higher fiscal 2026 revenue and adjusted earnings from operations, while outli
ATS (ATS) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") to
On May 20, 2026, Nordson Corp (NDSN) released its 8-K filing reporting record second-quarter fiscal
Securitize Reports First Quarter 2026 Results PR Newswire MIAMI, May 20, 2026 MIAMI
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that f
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”)
G's shares fall 9.4% despite Q1 results beating estimates. Weak Q2 revenue guidance overshadows stro
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of pa
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quart